Short- and long-term effects induced by repeated 6-OHDA intraventricular administration: A new progressive and bilateral rodent model of Parkinson's disease. (11th October 2017)

• Record Type: Journal Article
• Authors: Quiroga-Varela, A.; Aguilar, E.; Iglesias, E.; Obeso, J.A.; Marin, C.
• Is Part Of: Neuroscience. Volume 361(2017)
• Page Start: 144
• Page End: 156
• Publication Date: 2017-10-11
• Subjects: 6-OHDA 6-hydroxydopamine -- ICV intracerebroventricular -- MFB medial forebrain bundle -- MPTP 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine -- PBS phosphate buffer saline -- PD Parkinson's disease -- SNpc substantia nigra pars compacta -- VTA ventral tegmental area; Parkinson's disease -- 6-hydroxydopamine -- intracerebroventricular -- neurodegeneration; Neurochemistry -- Periodicals; Neurophysiology -- Periodicals; Neurology -- Periodicals; Neurochimie -- Périodiques; Neurophysiologie -- Périodiques; Neurochemistry; Neurophysiology; Electronic journals; Periodicals; Electronic journals; 612.8
• DOI: 10.1016/j.neuroscience.2017.08.017
• Languages: English
• ISSNs: 0306-4522

Abstract

Highlights: The repeated intracerebroventricular 6-OHDA model leads to bilateral and progressive motor alterations. The motor deficit has been associated with progressive nigrostriatal dopaminergic degeneration. This model is a useful tool to investigate early and late changes in parkinsonian brain and neuroprotective therapies. Abstract: The pathological hallmark of Parkinson's disease (PD) is the progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc), and the resulting striatal dopamine deficiency, which are responsible for the classic motor features. Although a diagnosis of PD relies on the clinical effects of dopamine deficiency, this disease is also associated with other neurotransmitter deficits that are recognized as causing various motor and non-motor symptoms. However, the cause of dopaminergic nigral neurodegeneration in PD and the underlying mechanisms remain unknown. While animal models are considered valuable tools with which to investigate dopaminergic cell vulnerability, rodent models usually fail to mimic the neurodegeneration progression that occurs in human PD. To find a convenient rat model for studying the progression of dopaminergic cell degeneration and motor signs, we have developed a progressive rodent model using a repeated daily, intraventricular administration of the neurotoxin 6-hydroxydopamine (6-OHDA) (100 µg/day) in awakened rats for 1 to 10 consecutive days. The short- (6-day) and long-term (32-day) progression of motor alterations was studied. This model leads to a bilateral and progressive increase in catalepsy (evident from the 3rd infusion in the short-term groups ( p < 0.01) and from the 7th infusion in the long-term groups ( p < 0.01), which was associated with a progressive nigrostriatal dopaminergic deficit. All together this makes the new model an interesting experimental tool to investigate the mechanisms involved in the progression of dopaminergic neurodegeneration.